Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Amyloid-β Inhibitor
D-KLVFFA is a potent inhibitor of Amyloid-β assembly, exhibiting an IC50 value of 2.6 μM. This peptide is utilized in research focused on Alzheimer's disease, providing insights into the mechanisms of amyloid plaque formation and potential therapeutic interventions. Its application can contribute to the understanding of neurodegenerative processes and the development of Alzheimer’s disease treatments. -
Amyloid-Beta and Tau Inhibitor
Aβ/tau aggregation-IN-1 is a selective inhibitor of amyloid-beta (Aβ1-42) β-sheet formation and tau protein aggregation. With KD values of 160 μM for Aβ1-42 and 337 μM for tau, this compound demonstrates significant potential in research related to neurodegenerative disorders such as Alzheimer's disease. Its ability to cross the blood-brain barrier further supports its use in studies aimed at understanding the pathophysiology of amyloid and tau accumulation in the central nervous system. -
Aβ/tau Protein Aggregation Inhibitor
DN5355 is a small molecule inhibitor of amyloid β protein (Aβ) and hyperphosphorylated tau protein aggregation. It effectively inhibits the formation of Aβ and tau fibrils while also promoting the disaggregation of pre-formed aggregates. This compound is valuable for research applications focused on Alzheimer's disease and the underlying mechanisms of protein aggregation associated with neurodegeneration. -
Aβ40 Aggregation Inhibitor
Biphenyl-3′,3,4,4′-tetrol (BPT) is a potent inhibitor of Aβ40 aggregation, targeting the aggregation process associated with amyloid-beta peptides. This compound is relevant for research into neurodegenerative diseases, particularly Alzheimer's disease, by facilitating studies aimed at understanding and potentially mitigating the pathological effects of amyloid plaque formation. -
Amyloid-β Inhibitor
Semilicoisoflavone B is an isoflavone derived from Glycyrrhiza uralensis Fisch, functioning primarily as an inhibitor of amyloid-β (Aβ) secretion. It reduces Aβ levels by inhibiting the expression and activity of β-secretase-1 (BACE1). This compound enhances PPARγ expression while simultaneously inhibiting STAT3 phosphorylation, leading to decreased BACE1 levels. Semilicoisoflavone B is relevant for research into Alzheimer's disease and mechanisms of neurodegeneration. -
Aβ Inhibitor
Aβ aggregation-IN-1 is a selective inhibitor of amyloid-beta aggregation, effectively targeting the fibrillogenesis process. It demonstrates significant biological activity with IC50 values of 3.92 µM for aggregation and 7.19 µM for disaggregation. Additionally, Aβ aggregation-IN-1 inhibits malondialdehyde formation, enhances intracellular reduced glutathione levels, and reduces caspase 3 activity in neuronal cells. This compound is valuable for research in Alzheimer's disease and related neurodegenerative disorders. -
AChE Inhibitor
Buntanetap L-Tartrate is a selective acetylcholinesterase (AChE) inhibitor with an IC50 of 22.2 nM. This compound functions as a neurotoxic protein translation inhibitor, targeting proteins such as amyloid precursor protein (APP), α-synuclein (αSYN), and huntingtin protein (HTT). By obstructing the mRNA translation of β-amyloid precursor protein, Buntanetap reduces its production and exhibits anti-inflammatory properties. Its applications include research related to Alzheimer's disease and Parkinson's disease. -
β-Amyloid Inhibitor
RI-OR2-TAT is a potent inhibitor of β-Amyloid oligomerization, enhanced by the incorporation of the HIV protein transduction domain TAT. This compound exhibits a binding affinity to Aβ42 fibrils with a Kd value ranging from 58 to 125 nM. RI-OR2-TAT effectively reduces Aβ aggregation and plaque formation, mitigates microglial activation and oxidative stress, and promotes neurogenesis by increasing the proliferation of young neurons in the dentate gyrus. It is a valuable tool for research focused on neurodegenerative diseases, particularly Alzheimer's disease. -
Aβ1-40 Aggregation Inhibitor
QR-0217 is a potent inhibitor of Aβ1-40 aggregation, exhibiting an IC50 value of 7.5 µM. This compound also demonstrates the ability to inhibit α-synuclein aggregation, making it useful in studies related to neurodegenerative diseases. Additionally, QR-0217 has been shown to mitigate memory impairments associated with Aβ neurotoxicity, providing a valuable tool for research on Alzheimer's disease and related conditions. -
β-amyloid Aggregation Inhibitor
Methyl tridecanoate is a β-amyloid aggregation inhibitor that demonstrates a moderate capacity to impede the formation of β-amyloid fibrils, which are implicated in neurodegenerative diseases such as Alzheimer's. Additionally, this compound displays weak inhibition of acetylcholinesterase (AChE), an enzyme involved in cholinergic neurotransmission. Its dual activity suggests potential applications in research focused on Alzheimer's pathology and related cognitive disorders. -
Amyloid-β Inhibitor
2-Hydroxy-5-(phenyldiazenyl)benzoic acid-d5 is a deuterated derivative of 2-Hydroxy-5-(phenyldiazenyl)benzoic acid that primarily targets amyloid-β. This compound exhibits significant inhibitory activity against amyloid-β aggregation, making it valuable for research related to Alzheimer's disease and other neurodegenerative disorders. It serves as a useful tool for investigating the mechanisms of amyloid pathology and potential therapeutic strategies. -
Aβ1–42 Aggregation Inhibitor
Aβ1–42 aggregation inhibitor 2 is a potent inhibitor of Aβ1-42 aggregation, which is significant in the study of Alzheimer's disease. This compound demonstrates strong antioxidant properties, effectively chelates metal ions, and alleviates oxidative stress. Additionally, it exhibits neuroprotective and anti-neuroinflammatory activities, making it a valuable tool for research focused on neurodegenerative disorders and potential therapeutic interventions. -
BACE1 Inhibitor
CTS-21166 is a selective inhibitor of β-site amyloid precursor protein cleaving enzyme 1 (BACE1), designed to penetrate the blood-brain barrier effectively. It demonstrates the ability to reduce levels of amyloid-beta (Aβ) in the brain, making it a valuable tool for studying the pathogenesis of Alzheimer's disease. CTS-21166 is suitable for use in both in vitro and in vivo research applications focused on Alzheimer's and related neurodegenerative disorders. -
Amyloid-β Inhibitor
YIAD-0205 is an orally bioavailable inhibitor of amyloid-β (Aβ) aggregation, specifically targeting Aβ(1-42). This compound exhibits significant in vivo efficacy in a transgenic mouse model of Alzheimer's disease carrying five familial mutations (5XFAD). Its application lies in Alzheimer's research, particularly in studies exploring therapeutic strategies aimed at mitigating Aβ-related neurodegeneration. -
Amyloid β Inhibitor
Aβ-IN-3 is a potent inhibitor of amyloid β (Aβ) aggregation, specifically targeting Aβ42. This compound effectively inhibits the aggregation of Aβ42, making it a valuable tool in the study of amyloid-related pathologies. However, Aβ-IN-3 does not mitigate the neurotoxicity associated with Aβ42 in SH-SY5Y cells, nor does it alter the aggregation state of Aβ42 into a non-toxic form. Its primary applications lie in research focused on Alzheimer's disease and amyloid aggregation mechanisms. -
Aβ Inhibitor
PPI-1019 is an amyloid beta (Aβ) inhibitor that specifically targets the aggregation of Aβ peptides. This compound demonstrates potential neuroprotective effects, making it a valuable tool for researching neurodegenerative disorders, particularly Alzheimer's disease. Its role in modulating Aβ-related toxicity makes PPI-1019 significant for studies aimed at understanding the pathophysiology of amyloid plaque formation and developing therapeutic strategies. -
Aβ Oligomers Formation Inhibitor
Aβ-IN-6 is an Aβ oligomers formation inhibitor that effectively reduces pro-inflammatory cytokine release from microglia. This compound significantly promotes Nrf2 nuclear translocation, thereby interfering with the aggregation of Aβ oligomers. Aβ-IN-6 offers neuroprotective effects through modulation of redox-sensitive signaling pathways in in vivo oxidative stress models. Its oral bioactivity and combined anti-inflammatory, antioxidant, and anti-oligomeric properties make Aβ-IN-6 a valuable reagent for research into Alzheimer's disease. -
NF-κB Inhibitor
6-O-p-Hydroxybenzoylglutinoside is a selective NF-κB inhibitor that effectively suppresses TNF-α-activated NF-κB transcriptional activity, with an IC50 of 52.78 μM. This compound demonstrates targeted biological activity without significantly inhibiting soluble epoxide hydrolase (sEH), acetylcholinesterase (AChE), or butyrylcholinesterase (BChE). Isolated from the seeds of Catalpa bungei (Manchurian catalpa), 6-O-p-Hydroxybenzoylglutinoside is valuable for research applications focused on inflammation and signal transduction pathways. -
QPCTL Inhibitor
QP5020 is a selective QPCTL inhibitor with an IC50 value of 15 nM. This compound demonstrates notable antitumor efficacy, making it a valuable tool for cancer research. Its mechanism of action provides insights into the role of QPCTL in tumor biology and offers potential avenues for therapeutic exploration. -
Aβ Aggregation Inhibitor
Aβ-IN-5 is a potent Aβ aggregation inhibitor, demonstrating oral bioavailability. It effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values of 21.29 μM and 1.32 μM, respectively. This compound exhibits significant neuroprotective effects while maintaining low neurotoxicity, making it a valuable tool for research on neurodegenerative diseases, particularly Alzheimer’s disease. -
Aβ42 Inhibitor
Doliroside A is an Aβ42-binding agent that exhibits an IC50 of 26.57 μM for Aβ42. By binding to Aβ42 nuclei and oligomers, it forms stable complexes that suppress Aβ42 fibrillation, redirecting it into off-pathway, amorphous oligomers. This compound serves as a valuable tool in Alzheimer's disease research, aiding in the understanding of Aβ42 aggregation mechanisms and potential therapeutic strategies. -
BACE1/2 Inhibitor
BACE1/2-IN-1 is a potent dual inhibitor of BACE1 and BACE2, exhibiting IC50 values of 0.01 μM and 0.0053 μM, respectively. This compound demonstrates a favorable pharmacokinetic profile characterized by a lower P-glycoprotein efflux ratio and enhanced passive permeability. In addition, BACE1/2-IN-1 is associated with increased metabolic stability in liver microsomes, making it a valuable tool for researching therapeutic strategies targeting amyloid precursor protein processing in Alzheimer's disease. -
BACE1 Inhibitor
2,2′,4,4′-Tetrahydroxychalcone is a selective and potent inhibitor of Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) with an IC50 of 0.62 μM. This compound, derived from Isoliquiritigenin found in Glycyrrhiza uralensis, effectively inhibits the β-cleavage of amyloid precursor protein (APP), leading to a reduction in β-amyloid (Aβ) peptide production. 2,2′,4,4′-Tetrahydroxychalcone is used in research related to Alzheimer's disease, providing insights into potential therapeutic avenues for neurodegenerative conditions. -
Cholinesterase (ChE) Inhibitor
hAChE/Aβ1-42-IN-1 is a potent cholinesterase (ChE) inhibitor that effectively inhibits human acetylcholinesterase (hAChE) and prevents the aggregation of Aβ1-42 peptides. This compound demonstrates favorable relative safety in HepG2 cell lines and exhibits excellent blood-brain barrier (BBB) penetration, exhibiting a wide safety margin. hAChE/Aβ1-42-IN-1 is a valuable tool for research focusing on Alzheimer's disease (AD) and related neurodegenerative conditions. -
BACE1 Inhibitor
AZ3971 is a selective BACE1 inhibitor that effectively penetrates the blood-brain barrier, while leaving γ-secretase activity unaffected. By reducing the production of amyloid-beta (Aβ), AZ3971 serves as a valuable tool in the study of Alzheimer's disease and related neurodegenerative disorders. Its oral bioavailability makes it particularly suitable for in vivo research applications. -
Aβ oligomerization Inhibitor
Aβ aggregation-IN-4 is an Aβ oligomerization inhibitor that targets and mitigates the neurotoxicity associated with amyloid-β protein (Aβ). By significantly reducing the formation of oligomeric complexes of Aβ (Aβ-OCs) without affecting total Aβ levels, it effectively attenuates Aβ oligomerization. This compound provides a valuable tool for researching the pathophysiology of Alzheimer's disease (AD) and exploring potential therapeutic strategies. Additionally, Aβ aggregation-IN-4 protects primary cortical neurons from oligomer-induced cell death, highlighting its relevance in neuroprotective studies. -
Tau/Amyloid-β Aggregation Inhibitor
TRV-1387 is a benzofurazan compound that functions as an inhibitor of tau and amyloid-β aggregation. It demonstrates significant biological activity in preventing the formation of toxic aggregates associated with neurodegenerative diseases, making it a valuable tool for research in Alzheimer's disease and related pathologies. TRV-1387 can be utilized to study the mechanisms of amyloid-related toxicity and to explore potential therapeutic strategies targeting protein aggregation. -
Tau/Aβ Inhibitor
D-687 is a selective inhibitor of Tau and amyloid-beta (Aβ) aggregation. It has demonstrated the ability to reverse Aβ1–42-induced neurotoxicity in SH-SY5Y neuronal cells, highlighting its significant neuroprotective effects. This compound is valuable for research focused on Alzheimer's disease and related neurodegenerative disorders. -
QC Inhibitor
Glutaminyl Cyclase Inhibitor 5 is a potent and selective inhibitor of human glutaminyl cyclase (hQC), exhibiting an IC50 value of 3.2 nM. This compound serves as a valuable tool for investigating the role of hQC in neurodegenerative diseases and related biological processes. It is applicable in various research studies focused on glutamate signaling and its implications in disease mechanisms. -
Tau/Aβ Inhibitor
D-688 is a potent inhibitor of Tau and amyloid-beta (Aβ), demonstrating significant neuroprotective properties. This compound effectively reverses Aβ1–42-induced toxicity in SH-SY5Y neuronal cells, making it a valuable tool for studying neurodegenerative processes. Additionally, D-688 improves the survival rate of Drosophila melanogaster models expressing the human tau protein isoform (2N4R), underscoring its potential in Alzheimer's disease research and related disorders. -
BuChE Inhibitor
BuChE-IN-6 is a potent and selective inhibitor of butyrylcholinesterase (BuChE), exhibiting IC50 values of 0.46 μM and 0.51 μM for equine and human BuChE, respectively. This compound also demonstrates the ability to inhibit self-aggregation of amyloid-beta 42 (Aβ42), making it a valuable tool for research related to neurodegenerative diseases. Its unique properties support investigations into cholinergic dysfunction and the pathogenesis of Alzheimer's disease. -
Lipid Droplet Formation Inhibitor
Beauveriolide III is a specific inhibitor of lipid droplet formation, effectively reducing lipid accumulation in mouse macrophages. This compound plays a significant role in studies focused on lipid metabolism and its implications in metabolic disorders. Its utility in research can aid in understanding the biological pathways regulating lipid storage and inflammation in macrophage-associated pathologies. -
hAChE/hBACE Inhibitor
hAChE/hBACE-1-IN-4 is a quinazoline derivative that functions as a dual inhibitor of human acetylcholinesterase (hAChE) and human β-site amyloid precursor protein cleaving enzyme 1 (hBACE-1). It exhibits potent inhibitory activity with IC50 values of 0.283 μM for hAChE and 0.231 μM for hBACE-1. This compound demonstrates the ability to inhibit amyloid-beta (Aβ) aggregation and shows favorable properties such as non-neurotoxicity, blood-brain barrier permeability, and oral bioavailability. hAChE/hBACE-1-IN-4 is suitable for research applications related to Alzheimer's disease. -
RAGE/SERT Inhibitor
RAGE/SERT-IN-1 is a potent inhibitor of receptor for advanced glycation end products (RAGE) and serotonin transporter (SERT), demonstrating IC50 values of 8.26 μM and 31.09 nM, respectively. This compound exhibits significant neuroprotective properties against Aβ25-35-induced neuronal damage and has been shown to alleviate depressive behaviors in murine models. RAGE/SERT-IN-1 is a valuable tool for studying the interplay between Alzheimer's disease and depression comorbidity. -
Aβ Aggregation Inhibitor
SEN 304 is an Aβ aggregation inhibitor that directly binds to Aβ(1-42), effectively delaying β-sheet formation while promoting the aggregation of toxic oligomers into a nontoxic form. This compound is primarily utilized in research focused on Alzheimer’s disease, providing insights into the mechanisms of neurodegeneration and potential therapeutic strategies. The ability of SEN 304 to modulate Aβ aggregation makes it a valuable tool for studying amyloid pathology. -
AChE Inhibitor
AChE-IN-19 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 0.56 μM. This compound also demonstrates the ability to inhibit amyloid beta (Aβ) aggregation, contributing to its neuroprotective properties. AChE-IN-19 has been shown to exert minimal toxicity on SH-SY5Y neuronal cells, making it a valuable tool for research applications related to Alzheimer's disease. -
Amyloid-β Inhibitor
Aβ Fibrillization Modulator 1 targets amyloid-β (Aβ) by stabilizing Aβ monomers, thus inhibiting the formation of toxic fibrils associated with neurodegenerative diseases. This compound demonstrates potential in research applications focused on Alzheimer's disease and other amyloid-related disorders. By modulating fibrillization, it provides a valuable tool for investigating the mechanisms of amyloid aggregation and the development of therapeutic strategies. -
Amyloid-β Inhibitor
AChE/Aβ-IN-5 is a bifunctional inhibitor that targets acetylcholinesterase (AChE) and reduces the auto-induced aggregation of amyloid-β (Aβ) peptides. This compound has demonstrated the ability to significantly ameliorate cognitive deficits induced by scopolamine and Aβ in murine models. It serves as a valuable tool for research into neurodegenerative diseases, particularly Alzheimer's disease, by providing insights into the mechanisms underlying cognitive impairment. -
Aβ42 Inhibitor
2002-G12 is an Aβ42 inhibitor that effectively reduces Aβ42 toxicity by 76%. Its mechanism of action makes it a valuable tool for investigating Alzheimer's disease and studying the role of Aβ42 in neurodegenerative processes. Researchers can utilize 2002-G12 to explore potential therapeutic strategies targeting amyloid-beta aggregation and toxicity. -
Amyloid-β Inhibitor
KMS88009 is a potent amyloid-β oligomer inhibitor that directly disrupts the formation of these aggregates. This compound demonstrates significant potential in preserving cognitive function when administered preventively and reversing cognitive decline therapeutically. In studies using the APP/PS1 double transgenic mouse model, KMS88009 effectively reduced amyloid-β oligomer assembly and improved cognitive performance. Comprehensive evaluations of its physicochemical properties, pharmacokinetics, and toxicity further underscore KMS88009's promise as a therapeutic candidate for Alzheimer's disease. -
AChE Inhibitor
Memoquin is an AChE inhibitor with significant anti-amyloid and antioxidant properties. It exhibits oral bioavailability and selectively inhibits BACE-1 and AChE, with IC50 values of 108 nM and 1.55 nM, respectively. Memoquin is noted for its ability to enhance cognitive function while preventing Aβ-induced neurotoxicity associated with oxidative stress. This compound is valuable for research into Alzheimer's disease and related neurodegenerative disorders. -
Beta-secretase inhibitor
β-Secretase-IN-5 is a potent inhibitor of beta-secretase, a key enzyme involved in the cleavage of amyloid precursor protein (APP). By selectively reducing the production of amyloid-beta peptides Aβ1-40 and Aβ1-42, this compound is essential for research into Alzheimer's disease mechanisms and therapeutic strategies. Its application in neurodegenerative studies provides valuable insights into potential treatments for Alzheimer's. -
AChE Inhibitor
Phenserine tartrate is a selective, noncompetitive inhibitor of acetylcholinesterase (AChE) derived from Physostigmine. This compound has been shown to reduce the formation of β-amyloid precursor protein (APP) and β-amyloid peptide (Aβ), key factors involved in Alzheimer's disease pathology. Phenserine tartrate has demonstrated potential in improving cognitive performance and may help slow the progression of Alzheimer's disease, making it a valuable tool for research in neurodegenerative disorders. -
ChE/Aβ1-42 Aggregation Inhibitor
ChE/Aβ1-42-IN-1 is a potent inhibitor of acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), and amyloid-beta peptide (Aβ1-42) aggregation, exhibiting IC50 values of 0.062 µM, 0.767 µM, and 1.227 µM, respectively. This compound demonstrates significant blood-brain barrier (BBB) penetration, making it a promising candidate for research into Alzheimer's disease. ChE/Aβ1-42-IN-1's multi-targeted mechanism positions it as a valuable tool for studying therapeutic strategies in neurodegenerative disorders. -
Aβ Aggregation Inhibitor
SEN-1269 is a potent inhibitor of Aβ aggregation, specifically targeting Aβ(1-42) oligomers. This compound protects neuronal cell lines from the detrimental effects of Aβ(1-42) exposure and mitigates deficits in long-term potentiation (LTP) and memory associated with Aβ oligomer toxicity. SEN-1269 serves as a valuable tool for research investigating the pathophysiology of Alzheimer's disease. -
AChE Inhibitor
hAChE-IN-10 is a potent inhibitor of human acetylcholinesterase (AChE), demonstrating an IC50 of 6.34 nM. This compound exhibits significant antioxidant properties and effectively scavenges free radicals. Additionally, hAChE-IN-10 has been shown to inhibit Cu2+-induced aggregation of Aβ1-42, reduce amyloid plaque formation, and provide neuroprotective effects. It has also been linked to the improvement of cognitive deficits in mouse models induced by scopolamine, making it a valuable tool for studying neurodegenerative diseases and cognitive impairment. -
Aβ42 Inhibitor
GL-522, a 4-sulfocalix[8]arene derivative, functions as an Aβ42 inhibitor by engaging in nonspecific and multipoint hydrophobic interactions, exhibiting a Kd of 276 μM. This compound effectively inhibits the fibrillation of Aβ42 and mitigates its cytotoxic effects, making it a valuable tool for research in Alzheimer's disease. Its ability to modulate amyloid aggregation and toxicity positions GL-522 as a significant reagent in neurodegenerative disease studies. -
Aβ Aggregation Inhibitor
AY1511 is an amyloid β (Aβ) aggregation inhibitor that demonstrates low cytotoxicity. This compound is utilized in research focusing on neurodegenerative diseases, particularly Alzheimer's disease, by inhibiting the aggregation of Aβ peptides. AY1511 serves as a valuable tool for studying the mechanisms of amyloid pathology and the development of potential therapeutic strategies. -
Aβ40/tau Aggregation Inhibitor
Tau/Aβ40 aggregation-IN-1 is a potent inhibitor of tau and Aβ40 aggregation, exhibiting IC50 values of 1.8 μM and 1.3 μM, respectively. This compound is of significant interest in Alzheimer's disease research, as it targets the pathological aggregation of tau protein and amyloid-beta peptides. Its effectiveness in modulating these protein interactions makes it a valuable tool for studying neurodegenerative mechanisms and potential therapeutic interventions. -
MAO-B Inhibitor
MAO-B-IN-50 is a selective inhibitor of monoamine oxidase B (MAO-B), demonstrating an IC50 value of 0.06 μM. This compound is effective in inhibiting the aggregation of amyloid-beta (Aβ40/42) and Tau proteins, with overall IC50 values near 1 μM. Additionally, MAO-B-IN-50 shows potent selective inhibition of acetylcholinesterase (AChE) with an IC50 of 1.78 μM. It is suitable for use in research related to Alzheimer's disease.
